Vincenza Conteduca
Foggia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 185 publications
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.
Journal: Expert review of anticancer therapy
Published: June 30, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.
Journal: Minerva urology and nephrology
Published: June 23, 2026
BRCA Testing in Prostate Cancer: A Histopathologist's Perspective.
Journal: Diagnostics (Basel, Switzerland)
Published: June 14, 2026
The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.
Journal: The oncologist
Published: February 08, 2026
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.
Journal: Therapeutic advances in medical oncology
Published: January 26, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.
Journal: Prostate cancer and prostatic diseases
Published: January 03, 2026
Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.
Journal: International journal of cancer
Published: December 24, 2025
YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 03, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.
Journal: JCO global oncology
Published: October 29, 2025
The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities.
Journal: Current oncology (Toronto, Ont.)
Published: October 25, 2025
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.
Journal: Cancer immunology, immunotherapy : CII
Published: October 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.
Journal: European urology open science
Published: October 16, 2025
Last Updated: 09/26/2026